These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34737134)

  • 21. An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects.
    Menegola E; Veltman CHJ; Battistoni M; Di Renzo F; Moretto A; Metruccio F; Beronius A; Zilliacus J; Kyriakopoulou K; Spyropoulou A; Machera K; van der Ven LTM; Luijten M
    Toxicology; 2021 Jun; 458():152843. PubMed ID: 34186166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated approach to testing and assessment for predicting rodent genotoxic carcinogenicity.
    Petkov PI; Schultz TW; Donner EM; Honma M; Morita T; Hamada S; Wakata A; Mishima M; Maniwa J; Todorov M; Kaloyanova E; Kotov S; Mekenyan OG
    J Appl Toxicol; 2016 Dec; 36(12):1536-1550. PubMed ID: 27225589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro carcinogenicity testing: present and future perspectives in pharmaceutical development.
    Kowalski LA
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):29-35. PubMed ID: 11727320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals.
    Luijten M; Corvi R; Mehta J; Corvaro M; Delrue N; Felter S; Haas B; Hewitt NJ; Hilton G; Holmes T; Jacobs MN; Jacobs A; Lamplmair F; Lewis D; Madia F; Manou I; Melching-Kollmuss S; Schorsch F; Schütte K; Sewell F; Strupp C; van der Laan JW; Wolf DC; Wolterink G; Woutersen R; Zvonar Z; Heusinkveld H; Braakhuis H
    Regul Toxicol Pharmacol; 2020 Dec; 118():104789. PubMed ID: 33035627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.
    van der Laan JW; Kasper P; Silva Lima B; Jones DR; Pasanen M
    Crit Rev Toxicol; 2016 Aug; 46(7):587-614. PubMed ID: 27116466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances.
    Jacobs MN; Colacci A; Louekari K; Luijten M; Hakkert BC; Paparella M; Vasseur P
    ALTEX; 2016; 33(4):359-392. PubMed ID: 27120445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
    Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
    Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Outcome Pathway Development for Assessment of Lung Carcinogenicity by Nanoparticles.
    Nymark P; Karlsson HL; Halappanavar S; Vogel U
    Front Toxicol; 2021; 3():653386. PubMed ID: 35295099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The OSIRIS Weight of Evidence approach: ITS mutagenicity and ITS carcinogenicity.
    Buist H; Aldenberg T; Batke M; Escher S; Klein Entink R; Kühne R; Marquart H; Pauné E; Rorije E; Schüürmann G; Kroese D
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):170-81. PubMed ID: 23357514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation.
    Combes R; Grindon C; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Oct; 36 Suppl 1():43-63. PubMed ID: 19025331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients.
    Gilmour N; Kern PS; Alépée N; Boislève F; Bury D; Clouet E; Hirota M; Hoffmann S; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Osmani A; Petersohn D; Sekine S; van Vliet E; Klaric M
    Regul Toxicol Pharmacol; 2020 Oct; 116():104721. PubMed ID: 32645429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of transgenic mice in carcinogenicity hazard assessment.
    Jacobson-Kram D; Sistare FD; Jacobs AC
    Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hazard identification, classification, and risk assessment of carcinogens: too much or too little? - Report of an ECETOC workshop.
    Felter SP; Boobis AR; Botham PA; Brousse A; Greim H; Hollnagel HM; Sauer UG
    Crit Rev Toxicol; 2020 Jan; 50(1):72-95. PubMed ID: 32133908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
    Contrera JF; DeGeorge JJ
    Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.